HC Wainwright Issues Pessimistic Forecast for ANIP Earnings

Posted by Brian Himes on Aug 18th, 2026

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) – Investment analysts at HC Wainwright decreased their FY2027 earnings estimates for ANI Pharmaceuticals in a report issued on Tuesday, August 11th. HC Wainwright analyst B. Folkes now forecasts that the specialty pharmaceutical company will post earnings of $8.09 per share for the year, down from their previous estimate of $8.11. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $8.03 per share.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last released its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same quarter last year, the business earned $1.80 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS.

A number of other brokerages have also recently commented on ANIP. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Canaccord Genuity Group cut their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Finally, Guggenheim reduced their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.83.

Check Out Our Latest Analysis on ANI Pharmaceuticals

ANI Pharmaceuticals Trading Down 0.7%

Shares of NASDAQ ANIP opened at $76.00 on Tuesday. ANI Pharmaceuticals has a 1-year low of $70.15 and a 1-year high of $99.50. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The business’s 50 day moving average is $80.73 and its two-hundred day moving average is $78.99. The stock has a market capitalization of $1.75 billion, a P/E ratio of 16.38 and a beta of 0.44.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently modified their holdings of ANIP. KBC Group NV purchased a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $28,000. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. Hantz Financial Services Inc. grew its holdings in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $48,000. Finally, State of Wyoming acquired a new stake in shares of ANI Pharmaceuticals in the second quarter worth approximately $50,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the completion of the transaction, the director directly owned 38,878 shares in the company, valued at $3,144,452.64. This trade represents a 4.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the sale, the vice president directly owned 74,424 shares in the company, valued at $5,617,523.52. The trade was a 0.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 18,987 shares of company stock valued at $1,546,405. Company insiders own 8.10% of the company’s stock.

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.